Karyopharm Therapeutics (KPTI) Gross Profit (2019 - 2026)

Karyopharm Therapeutics (KPTI) has 6 years of Gross Profit data on file, last reported at $32.6 million in Q4 2025.

• Quarterly Gross Profit rose 11.49% year-over-year to $32.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $140.2 million (up 0.56% YoY) and the FY2025 annual result came in at $140.3 million, up 0.58% from the prior year.
• Gross Profit declined to $32.6 million in Q4 2025, from $41.9 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $125.5 million in Q4 2021 to a low of $21.5 million in Q2 2021.
• A 5-year average of $39.9 million and a median of $36.4 million in 2023 frame the typical range for Gross Profit.
• The widest YoY moves for Gross Profit: up 80.5% in 2022, down 74.56% in 2022.
• Tracing KPTI's Gross Profit over 5 years: stood at $125.5 million in 2021, then tumbled by 74.56% to $31.9 million in 2022, then climbed by 2.17% to $32.6 million in 2023, then decreased by 10.33% to $29.3 million in 2024, then climbed by 11.49% to $32.6 million in 2025.
• The last three Gross Profit figures came in at $32.6 million (Q4 2025), $41.9 million (Q3 2025), and $36.9 million (Q2 2025), per Business Quant data.